2012 ACR/ARHP Annual Meeting

November 9-14, 2012. Washington, DC.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1563

Is Automated DATA Capture As Reliable As Manual DATA Entry in Survey Based Research?
Abstract Number: 130

Is Bone Scintigraphy Still Useful to Diagnose Rheumatoid Arthritis After the Appearance of 2010 ACR/EULAR Classification Criteria?
Abstract Number: 2211

Is It Useful to Repeat an MRI of the Sacroiliac Joints in the Diagnostic Work-up for Spondyloarthritis?
Abstract Number: 770

Is Late Onset Rheumatoid Arthritis (LORA) Really a Distinct Entity of RA? Results From the Swiss Observational Cohort
Abstract Number: 1877

Is the Amount of T and B Lymphocytes, Natural Killer Cells and Macrophages in Biopsies From Non-Ruptured Chronic Tendinopathic Achilles Tendons Predictive for Long Term Outcome? A >3 Years Prospective Study of 37 Patients
Abstract Number: 357

Is the Impact of Methotrexate On Mortality in Rheumatoid Arthritis Independent of Its Effect On Disease Activity?
Abstract Number: 1955

Is the Pattern of Capillary Deposition of Complement Membrane Attack COPMLEX Useful in the Differential Diagnosis of Inflammatory?
Abstract Number: 2068

Is There a Difference in Rheumatology Patient Reported Outcomes When Measured At Home Versus the Clinic Setting?
Abstract Number: 928

Is There an Optimal Treatment Strategy for Disease-Modifying-Antirheumatic-Drug Naïve Patients with Rheumatoid Arthritis?
Abstract Number: 944

Job-Related Burden and Effort-Reward Imbalance in Patients with Systemic Lupus Erythematosus
Abstract Number: 2114

Joint Damage Progression in Rheumatoid Arthritis: Role of the HLA-DRB1 Shared Epitope and Anti-CCP
Abstract Number: 442

Joint Effects of Known Genetic Markers of Rheumatoid Arthritis Risk and 25-Hydroxyvitamin D On Rheumatoid Arthritis Risk
Abstract Number: 199

Joint, Hand and Feet Swelling As a Presenting Symptom of Hereditary Angioedema
Abstract Number: 2018

Juvenile Idiopathic Arthritis in Adulthood: Evaluation of Disease Activity, Damage and Quality of Life
Abstract Number: 957

Key Psychological Processes Associated with the Fibromyalgia Phenotype Exist On a Continuous Spectrum with Asymptomatic People

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].